rademikibart intravenous (CBP 201 IV) / Suzhou Connect Biopharma - LARVOL DELTA

Rademikibart IV for Acute Asthma and COPD Exacerbation (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: Connect Biopharm LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

In August 2026, the Company initiated the Phase 2 Seabreeze STAT IV study, an open-label, single-arm trial to evaluate intravenous (IV) rademikibart as an add-on treatment for an acute exacerbation in 40 participants with asthma or COPD with type 2 inflammation who require an urgent healthcare visit, similar to the Phase 2 Seabreeze STAT asthma and COPD studies. (The Manila Times) - "The Seabreeze STAT IV study is being conducted at a number of the same clinical sites that completed the Seabreeze STAT asthma and COPD studies and is designed to bridge 600 mg subcutaneous to 300 mg IV push administration for treating acute exacerbations."

Trial status • Asthma • Chronic Obstructive Pulmonary Disease • Immunology